vancomycin has been researched along with gemifloxacin in 11 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (45.45) | 29.6817 |
2010's | 6 (54.55) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
Dang, Z; Ji, R; Yang, Y; Zhang, S | 1 |
Chang, KY; Ho, YH; Hsieh, YC; Hsueh, PR; Huang, LM; Huang, YC; Lin, HC | 1 |
Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH | 1 |
Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
Bradbury, BJ; Deshpande, M; Phadke, AS; Pucci, MJ; Thanassi, JA; Wiles, JA | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
1 review(s) available for vancomycin and gemifloxacin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
10 other study(ies) available for vancomycin and gemifloxacin
Article | Year |
---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Synthesis and antibacterial activity of novel fluoroquinolones containing substituted piperidines.
Topics: Anti-Bacterial Agents; Bacteria; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Piperidines | 2007 |
Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactams; Genotype; Humans; Microbial Sensitivity Tests; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae; Taiwan | 2008 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin | 2010 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
Topics: Anti-Bacterial Agents; Cell Line, Tumor; DNA Topoisomerase IV; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Organoselenium Compounds; Piperidines; Quinolines; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Topoisomerase II Inhibitors | 2011 |
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |